Skip to main content

Table 2 Univariate survival analysis based on KRAS status or SLFN11 expression status

From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

    DFS OS
   No. 3y-DFS(%) HR(95 %CI) P 5y-OS HR(95 %CI) P
Patients with KRAS wt         
  SLFN11high 23 91.3 0.347(0.083–1.449) 0.147 100.0   0.05
  SLFN11low 130 75.8 1   83.3   
Patients with KRAS mt         
  SLFN11high 12 72.9 1.424(0.391–5.188) 0.592 80.2 1.348(0.279–6.508) 0.71
  SLFN11low 51 83.9 1   81.9 1  
Patients with SLFN11high         
  KRAS wt 23 91.3 1 0.207 100.0   0.06
  KRAS mt 12 72.9 3.167(0.528–18.979)   80.2   
Patients with SLFN11low         
  KRAS wt 130 75.8 1 0.511 80.5   0.503
  KRAS mt 51 83.9 0.787(0.386–1.607)   81.9 0.749(0.321–1.746)